Ario Pharma focusses on the development of drugs for the treatment of respiratory indications. Ario is evaluating the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials which will separately recruit Chronic Obstructive Pulmonary Disease (COPD) patients and chronic idiopathic cough patients. Ario is also developing TRPA1 antagonists for asthma and other inflammatory diseases. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease.
| Website | http://www.ariopharma.com |
| Revenue | $6.2 million |
| Employees | 3 (0 on RocketReach) |
| Founded | 2010 |
| Phone | +44 1223 493922 |
| Technologies |
HTML
,
Twitter
,
Google Analytics
+7 more
(view full list)
|
| Industry | Pharmaceuticals, Biotechnology, Biopharma, Drug Discovery, Healthcare, Drug Manufacturing & Research, Health Care, Science and Engineering, Pharmaceutical |
| Keywords | Respiratory Therapeutics, Pharmaceutical, Drug Development, Pharmaceutical Research, Drug Discovery, Clinical Trials, Innovative Medicines, Biopharma, Medical Research, Phase 2 Trials, New Drug Candidates, Pain Management |
| Competitors | Novartis, Pfizer, AstraZeneca, Amgen, Regeneron, Gilead Sciences, Vertex Pharmaceuticals, BioMarin Pharmaceutical Inc., Lilly India, Sarepta Therapeutics, Inc. +41 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 2834 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Ario Pharma employee's phone or email?
Ario Pharma Questions
The Ario Pharma annual revenue was $6.2 million in 2026.
Ario Pharma is based in Cambridge, Cambridgeshire.
The NAICS codes for Ario Pharma are [3254, 32541, 32, 325].
The SIC codes for Ario Pharma are [28, 283, 2834].
Related Companies
